Please assess the completion status of the following clinical trial:

Trial Title: The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntarily gives informed consent to participate in the study.~2. Right heart catheterization demonstrating conventional mean pulmonary artery pressure (mPAP) \>25, pulmonary vascular resistance (PVR) \>3.0 Wood Units, pulmonary capillary wedge pressure (PCWP) \<16 mmHg within two years of enrollment~3. Subject is 18 years of age or older at Screening.~4. Diagnosis of symptomatic idiopathic or heritable PAH, PAH associated with Connective Tissue Disease (CTD), PAH associated with repaired/unrepaired congenital systemic-to-pulmonary shunt, Portopulmonary hypertension or PAH associated with HIV infection.~5. New York Heart Association Functional Class II or III~6. Stable therapy with ambrisentan 5 or 10 mg every day for \> 90 days.~7. Baseline 6-Minute Walk Distance 50-450m~Exclusion Criteria:~1. Substantial Primary Lung disease~   * forced expiratory volume at one second (FEV-1)/forced vital capacity (FVC) \<0.6 and FEV-1 \<70% predicted~  * diffusing capacity of lung for carbon monoxide (DLCO) \<30% predicted~  * Pulmonary fibrosis~2. Left ventricular ejection fraction \< 50%~3. Pulmonary capillary wedge pressure \> 16 mm Hg~4. Aortic valve disease~5. Ischemic heart disease~6. Systemic hypotension (SBP \<90 mm Hg)~7. Co-existing treatment with other endothelin receptor antagonists or prostacyclin analogues~8. New York Heart Association Functional Class IV~9. Chronic thromboembolic pulmonary hypertension~10. Known or suspected pulmonary veno-occlusive disease~11. Serum creatinine \>2.0 mg/dL in women, Serum creatinine \>2.5 mg/dL in men~12. Baseline serum potassium \>5.0 milliequivalent (mEq)/L~13. Participation in ongoing drug/intervention-based clinical trial~14. Pregnancy~15. Unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMB + Spiro, Cardiopulmonary fitness (Type: ACTIVE_COMPARATOR): Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
- Placebo Cardiopulmonary fitness (Type: PLACEBO_COMPARATOR): Placebo mimics spironolactone 50 mg and will be taken QD

Based on this trial design, predict the completion outcome and termination type (if applicable).